Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FA-DABA-SMA
- Development stage
- Preclinical
- Lead developer
- Queen's University
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
FA-DABA-SMA is a 350 kDa folate-functionalized amphiphilic alternating copolymer developed as an intrinsic, "drug-free" nanotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The molecule consists of a styrene maleic anhydride (SMA) backbone functionalized with folate (FA) via a 2,4-diaminobutyric acid (DABA) linker. Unlike traditional nanocarriers that require an encapsulated cytotoxic payload, FA-DABA-SMA possesses inherent biological activity through multivalent engagement with folate receptors. This interaction triggers the sequestration of Hippo pathway effectors, Yes-associated protein 1 (YAP) and WW domain-containing transcription regulator protein 1 (TAZ), in the cytoplasm, thereby preventing their nuclear translocation and inhibiting oncogenic signaling. Additionally, FA-DABA-SMA suppresses hypoxic survival pathways, including Hypoxia-inducible factor 1-alpha (HIF-1α), Vascular endothelial growth factor (VEGF), and Carbonic anhydrase 9 (CA9), and abrogates vasculogenic mimicry and metastasis to the liver and lungs.
- Other names
- folate-functionalized amphiphilic alternating copolymer
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on FA-DABA-SMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FA-DABA-SMA.